AI Article Synopsis
- GLP-1 receptor agonists (GLP-1 RAs) are gaining popularity for managing blood sugar in type 2 diabetes and aiding in weight loss.
- They may also offer benefits for neurological conditions beyond their effects on glucose levels.
- The review examines existing research to inspire new studies on the potential neurological advantages of GLP-1 RAs, especially in relation to surgery.
Article Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an increasingly popular class of medications commonly used for glycemic control in patients with type 2 diabetes mellitus and for weight loss. GLP-1 RAs also have potential benefits in patients with various neurological diseases independent of their glucose-modulating effect. In this focused review, we explore animal and clinical evidence evaluating the impact of GLP-1 RAs in common neurological diseases. Our aim is to provide a basis for hypothesis generation for future studies to assess the role that GLP-1 RAs may have on the nervous system, including implications for the perioperative period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ANA.0000000000000985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- GLP-1 receptor agonists (GLP-1 RAs) may reduce major kidney events and all-cause mortality in patients with type 2 diabetes and chronic kidney disease (CKD).
- A systematic review included 10 studies involving over 18,000 patients, showing significant benefits with GLP-1 RAs compared to placebo.
- There were no significant differences in cardiovascular events or mortality, indicating more research may be needed in those areas.
Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes.
J Intern Med
December 2024
RICORS2040, Madrid, Spain.
Chronic kidney disease (CKD) is a prevalent and progressive condition associated with significant mortality and morbidity. Diabetes is a common cause of CKD, and both diabetes and CKD increase the risk of cardiovascular disease (CVD), the leading cause of death in individuals with CKD. This review will discuss the importance of early detection of CKD and prompt pharmacological intervention to slow CKD progression and delay the development of CVD for improving outcomes.
View Article and Find Full Text PDFGLP-1 RECEPTOR AGONISTS USE AND INCIDENCE OF GLAUCOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS: GLP-1 receptor agonists use and incidence of glaucoma.
Am J Ophthalmol
December 2024
Glaucoma Service, Wills Eye Hospital, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Introduction: In diabetics, glucagon-like peptide 1 (GLP-1) receptor agonists (RA) may protect against microvascular alterations and oxidative stress, both of which have been implicated in glaucoma. Multiple studies suggest a possible relation between GLP-1 RA use and the development of glaucoma. This study performs a systematic review of the literature regarding the incidence of glaucoma development in type 2 diabetes patients treated with GLP-1 receptor agonists compared to a control group.
View Article and Find Full Text PDFAnti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review.
Diabetes Obes Metab
December 2024
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for anti-obesity indications. However, little is known of the comparative effect of GLP-1 RAs and their glycemic impact across the different routes of administration, diabetic statuses and durations of prescription. PubMed, EMBASE and CENTRAL were searched from inception to 13 February 2024.
View Article and Find Full Text PDFGLP-1 receptor agonists significantly impair taste function.
Physiol Behav
December 2024
Smell and Taste Center, Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address:
Over 10 % of the US population are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to combat obesity. Although they decrease cravings for foods, their influence on chemosensory function is unknown. We employed state-of-the-art quantitative taste and smell tests to address this issue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!